New hope for PNH patients with persistent anemia: experimental drug VSA012 enters human testing
NCT ID NCT06848296
First seen May 08, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This early-stage study tests an investigational drug called VSA012 in about 50 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Participants either have not used complement inhibitors or still have low red blood cell counts despite prior treatment. The main goals are to check safety and see if the drug improves blood markers like LDH and hemoglobin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.